Across TCGA pan-cancer cohorts, PI4KAP1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PI4KAP1 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PI4KAP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PI4KAP1 expression acts as an unfavorable survival marker.
BLCA, LIHC, and UCEC are the cancer types where PI4KAP1 Mutation most reproducibly stratifies survival.